NEWSROOMPress ReleasesNewsPress Releases April 9, 2024 Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment March 6, 2024 Onchilles Pharma Announces Two Presentations of New Preclinical Data for N17350 and N17465 at AACR 2024 November 3, 2023 Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic September 27, 2023 Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023 April 19, 2023 Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity March 14, 2023 Onchilles Pharma Announces Presentation of Preclinical Data for N17350 at AACR 2023 December 12, 2022 Onchilles Pharma Nominates First Drug Development Candidate Targeting Neutrophil Biology for the Treatment of Cancer June 10, 2021 Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer PathwayNews January 5, 2024 Drug Target Review: Transforming Cancer Treatment for Greatest Impact June 20, 2021 SDBJ: Onchilles Pharma Raises $7M for Targeted Cancer Therapy June 15, 2021 BioWorld: Onchilles looks for cancer’s Achilles heel with a $7M series A June 10, 2021 Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway June 10, 2021 Could neutrophils be the secret to cancer’s Achilles’ heel? June 10, 2021 Cancer’s Achilles Heel? UChicago Startup Secures $7 Million to Develop Unique Treatment June 8, 2021 Nature Reviews Drug Discovery: A Protease with Far-Reaching Anti-Cancer Effects May 21, 2021 Cancer Discovery: The Serine Protease Neutrophil Elastase Selectively Kills Tumor Cells
